Co-Authors
This is a "connection" page, showing publications co-authored by Andy Goren and Carlos Wambier.
Connection Strength
8.110
-
Reply to comment on: The Gabrin sign. J Am Acad Dermatol. 2021 03; 84(3):e149-e150.
Score: 0.916
-
Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals. J Am Acad Dermatol. 2020 12; 83(6):e401-e402.
Score: 0.902
-
Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 12; 83(6):e453-e454.
Score: 0.895
-
Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682.
Score: 0.883
-
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020 Jul; 83(1):308-309.
Score: 0.876
-
Time of onset and duration of post-COVID-19 acute telogen effluvium. J Am Acad Dermatol. 2021 10; 85(4):975-976.
Score: 0.239
-
Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
Score: 0.239
-
SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study. Ann Thyroid. 2022 Mar; 6.
Score: 0.234
-
Potential risk for developing severe COVID-19 disease among anabolic steroid users. BMJ Case Rep. 2021 Feb 26; 14(2).
Score: 0.233
-
Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
Score: 0.229
-
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
Score: 0.229
-
Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol Venereol. 2021 Feb; 35(2):e101-e104.
Score: 0.228
-
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e15-e17.
Score: 0.227
-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
Score: 0.227
-
Are night shift workers at an increased risk for COVID-19? Med Hypotheses. 2020 Nov; 144:110147.
Score: 0.224
-
Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Front Med (Lausanne). 2020; 7:453.
Score: 0.224
-
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020 Oct; 143:110112.
Score: 0.223
-
Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543.
Score: 0.222
-
Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 11; 81(7):771-776.
Score: 0.221
-
A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547.
Score: 0.220
-
What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365.
Score: 0.219